Edesa Biotech (NASDAQ:EDSA) Announces Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Edesa Biotech (NASDAQ:EDSA) issued its quarterly earnings data on Friday. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.17), Zacks reports. During the same period in the prior year, the company earned ($0.54) EPS.

Edesa Biotech Trading Down 17.2 %

EDSA opened at $2.69 on Friday. The firm has a market cap of $9.33 million, a price-to-earnings ratio of -1.39 and a beta of 0.85. Edesa Biotech has a 12 month low of $1.55 and a 12 month high of $5.99. The stock has a fifty day moving average price of $1.86 and a 200-day moving average price of $3.13.

Edesa Biotech Company Profile

Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.